Evaluating the potency of HIV‐1 protease drugs to combat resistance
Authors:
- 14 November 2007
- journal article
- research article
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 71 (3) , 1163-1174
Abstract
HIV‐1 protease has been an important drug target for the antiretroviral treatment of HIV infection. The efficacy of protease drugs is impaired by the rapid emergence of resistant virus strains. Understanding the molecular basis and evaluating the potency of an inhibitor to combat resistance are no doubt important in AIDS therapy. In this study, we first identified residues that have significant contributions to binding with six substrates using molecular dynamics simulations and Molecular Mechanics Generalized Born Surface Area calculations. Among the critical residues, Asp25, Gly27, Ala28, Asp29, and Gly49 are well conserved, with which the potent drugs should form strong interactions. We then calculated the contribution of each residue to binding with eight FDA approved drugs. We analyzed the conservation of each protease residue and also compared the interaction between the HIV protease and individual residues of the drugs and substrates. Our analyses showed that resistant mutations usually occur at less conserved residues forming more favorable interactions with drugs than with substrates. To quantitatively integrate the binding free energy and conservation information, we defined an empirical parameter called free energy/variability (FV) value, which is the product of the contribution of a single residue to the binding free energy and the sequence variability at that position. As a validation, the FV value was shown to identify single resistant mutations with an accuracy of 88%. Finally, we evaluated the potency of a newly approved drug, darunavir, to combat resistance and predicted that darunavir is more potent than amprenavir but may be susceptible to mutations on Val32 and Ile84. Proteins 2008.Keywords
Funding Information
- NSF PFC-sponsored Center for Theoretical Biological Physics (PHY-0216576, PHY-0225630)
- NIH (5 T32DK07233)
- Center for AIDS Research at UCSD
This publication has 47 references indexed in Scilit:
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculationsJournal of Computational Chemistry, 2003
- Insights into Protein–Protein Binding by Binding Free Energy Calculation and Free Energy Decomposition for the Ras–Raf and Ras–RalGDS ComplexesJournal of Molecular Biology, 2003
- The Protein Data BankNucleic Acids Research, 2000
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP modelThe Journal of Physical Chemistry, 1993
- HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteinsBiochemical and Biophysical Research Communications, 1988
- Molecular dynamics with coupling to an external bathThe Journal of Chemical Physics, 1984
- Comparison of simple potential functions for simulating liquid waterThe Journal of Chemical Physics, 1983